![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-desktop-headergif-65408.gif)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-mobile-headergif-45399.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/25/2918702/0/en/Sol-Gel-Announces-the-Signing-of-Six-Exclusive-License-Agreements-to-Commercialize-TWYNEO-and-EPSOLAY-in-Europe-and-South-Africa.html
https://www.globenewswire.com/news-release/2024/07/15/2912937/0/en/Sol-Gel-Technologies-Announces-Management-Realignment.html
https://www.globenewswire.com/news-release/2024/05/28/2888890/0/en/Sol-Gel-Announces-Receipt-of-Nasdaq-Minimum-Price-Notice.html
https://www.globenewswire.com/news-release/2024/05/20/2884749/0/en/Sol-Gel-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Updates.html
https://www.globenewswire.com/news-release/2024/05/16/2883213/0/en/Sol-Gel-and-Beimei-Pharma-Announce-an-Asset-Purchase-Agreement-to-Commercialize-TWYNEO-in-the-Mainland-of-China-Hong-Kong-Macau-Taiwan-and-Israel.html
https://www.globenewswire.com/news-release/2024/04/01/2855070/0/en/Sol-Gel-s-Collaboration-Partner-First-to-File-ANDA-Drug-Product-Generic-to-Zoryve-Cream.html
https://www.globenewswire.com//news-release/2024/03/13/2845296/0/en/Sol-Gel-Reports-Full-Year-2023-Financial-Results-and-Corporate-Developments.html
https://www.globenewswire.com//news-release/2023/11/30/2788454/0/en/Sol-Gel-Technologies-Screens-First-Patient-for-SGT-610-Phase-3-Study.html
https://www.globenewswire.com//news-release/2023/11/28/2786910/0/en/Sol-Gel-Technologies-Ltd-to-Host-Virtual-KOL-Event-on-Gorlin-Syndrome-and-the-Upcoming-Phase-3-Trial-for-SGT-610.html
https://www.globenewswire.com//news-release/2023/11/09/2777169/0/en/Sol-Gel-Technologies-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html